Benzinga · Jul 15, 2026
Aldeyra Therapeutics To Request FDA Type D Meeting On NDA Of Reproxalap Resubmission By End Of Q3 2026
SEC Filing
AL
NASDAQ · ALDX
Aldeyra Therapeutics, Inc.
Healthcare · Biotechnology
$1.34
Down-$0.12 (-8.22%)
Updated Sep 12, 2026, 2:24 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 328.49M
- P/E ratio
- -7.6
- Dividend yield
- 0.00%
- 52-week range
- $1.07 – $5.60
- Volume
- 1.57M
- Avg. volume
- 1.07M
Price performance
ALDX price history
1M range · 20 trading sessions · Daily adjusted prices
ALDX closed at $1.34 after 20 trading sessions, down 14.10% for the selected period.
- Last close
- $1.34
- Period change
- -14.10%
- Period low
- $1.34
- Period high
- $1.58
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $1.48 | $1.48 | $1.33 | $1.34 | 1.57M |
| Sep 10, 2026 | $1.48 | $1.505 | $1.46 | $1.46 | 552.54K |
| Sep 9, 2026 | $1.53 | $1.535 | $1.495 | $1.50 | 544.21K |
| Sep 8, 2026 | $1.47 | $1.55 | $1.47 | $1.54 | 721.82K |
| Sep 4, 2026 | $1.47 | $1.49 | $1.46 | $1.48 | 486.18K |
| Sep 3, 2026 | $1.48 | $1.5111 | $1.46 | $1.48 | 568.93K |
| Sep 2, 2026 | $1.51 | $1.54 | $1.46 | $1.49 | 498.45K |
| Sep 1, 2026 | $1.46 | $1.50 | $1.455 | $1.49 | 462.87K |
| Aug 31, 2026 | $1.51 | $1.51 | $1.465 | $1.48 | 495.39K |
| Aug 28, 2026 | $1.52 | $1.56 | $1.48 | $1.485 | 547.98K |
| Aug 27, 2026 | $1.57 | $1.581 | $1.525 | $1.54 | 277.45K |
| Aug 26, 2026 | $1.54 | $1.575 | $1.52 | $1.56 | 478.95K |
| Aug 25, 2026 | $1.52 | $1.56 | $1.50 | $1.55 | 447.17K |
| Aug 24, 2026 | $1.53 | $1.545 | $1.4601 | $1.52 | 531.99K |
| Aug 21, 2026 | $1.50 | $1.595 | $1.475 | $1.52 | 1.1M |
| Aug 20, 2026 | $1.57 | $1.575 | $1.495 | $1.50 | 942.95K |
| Aug 19, 2026 | $1.59 | $1.60 | $1.54 | $1.58 | 982.2K |
| Aug 18, 2026 | $1.54 | $1.595 | $1.505 | $1.55 | 703.03K |
| Aug 17, 2026 | $1.55 | $1.58 | $1.525 | $1.56 | 789.81K |
| Aug 14, 2026 | $1.49 | $1.57 | $1.445 | $1.56 | 830.98K |
Latest ALDX news
The latest Smart Investors Daily articles mentioning ALDX.
Stock researchCompany · Overview
ALDX research
Overview
Company profile and research snapshot.
Company profile
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $7.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 18, 2026 | HC Wainwright & Co. | Neutral | — |
| Nov 10, 2025 | BTIG | Buy | — |
| May 19, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 7, 2025 | BTIG | Buy | — |
| Apr 4, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Jul 10, 2026
Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL
Aldeyra Therapeutics plunges after a third FDA CRL for reproxalap. Click here to read my most recent analysis of Aldeyra Therapeutics stock.
Yahoo · Feb 25, 2026
Aldeyra Therapeutics CEO Highlights Reproxalap Ahead of March 16 FDA Decision at Oppenheimer Conference
Aldeyra Therapeutics (NASDAQ:ALDX) CEO Todd Brady provided an update on the company’s late-stage ophthalmology programs and broader pipeline during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, with much of the discussion centered on the pending FDA decision for r
Yahoo · Feb 19, 2026
Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect?
The consensus price target hints at a 79.3% upside potential for Aldeyra Therapeutics (ALDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
